Phosphagenics Limited, an Australian drug delivery technology company will be collaborating with the United States Department of Agriculture’s (USDA), Agricultural Research Service (ARS) to develop trial products targeting mastitis, which is a serious bacterial infection effecting dairy cattle.
The collaboration will see Phosphagenics and ARS formulating and assessing products to combat the infection and will include a formulation that was previously trailed by Phosphagenics, combined with a vitamin D derivative according to a press release from asx.com.au.
A study conducted by the ARS last year found that by directly infusing a vitamin D derivative into infected areas of the mammary gland, bacteria levels and symptoms of mastitis were reduced. The study also found that treated cows delivered excellent milk production.
Mastitis currently affects approximately 15 percent of the global dairy population with economic loses estimated at US$2 b per annum.
Currently, treatment of the infection involves the use of antibiotics and the new formulation has been created to avoid the issues surrounding antibiotic resistant bacteria.
The trail is due to commence in mid 2013.
Image credit Dave Young via flickr